In vitro and in vivo antibacterial activity of doripenem
|
Accession number;05A0663309
|
| Title;In vitro and in vivo antibacterial activity of doripenem |
| Author;
NISHINO TAKESHI
(Kyoto Pharmaceutical Univ., JPN)
OTSUKI MASAKO
(Kyoto Pharmaceutical Univ., JPN)
IZAWA MASAAKI
(Kyoto Pharmaceutical Univ., JPN)
|
Journal Title;Japanese Journal of Chemotherapy
|
Journal Code:F0608A
|
ISSN:1340-7007
|
|
VOL.53;NO.Supplement 1;PAGE.32-46(2005)
|
| Figure&Table&Reference;FIG.8, TBL.7, REF.16 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;In vitro and in vivo antibacterial activity of a new carbapenem antibiotic, doripenem (DRPM), was compared to that of imipenem (IPM), panipenem (PAPM), meropenem (MEPM), ceftazidime (CAZ), and cefpirome (CPR). DRPM showed a broad antibacterial spectrum against gram-positive bacteria such as Staphylococcus aureus and gram-negative bacteria including Pseudomonas aeruginosa. DRPM was 2-fold more active than MEPM against MSSA: MIC90 of DRPM was 0.1 .MU.g/mL. Against Pseudomonas aerzcginosa, DRPM was more potent than PAPM and CAZ and the same as IPM and MEPM, with MIC90 of 3.13 .MU.g/mL. DRPM showed potent bactericidal activity against E. coli and Pseudomonas aeruginosa. Against Pseudomonas aeruginosa, DRPM showed a postantibiotic effect of 2.0 h the same as IPM. Therapeutic effects of DRPM were examined using an experimental infection model in mice. The efficacy of DRPM against systemic infection of Pseudomonas aeruginosa was equivalent to imipenem/cilastatin (IPM/CS) and meropenem/cilastatin (MEPM/CS) and was superior to CAZ. DRPM showed activity equal to IPM/CS and MEPM/CS in local K. pneumoniae and E. coli infection. (author abst.) |
|
|
|
Related Articles;
|
|
